Publications by authors named "Annemarie Moseley"
Article Synopsis
- * Researchers tested immunotherapy by using genetically modified T cells with a PRAME-specific TCR, which effectively killed medulloblastoma cells and suppressed tumor growth in mouse models.
- * A safety mechanism involving an inducible caspase-9 gene was included in the T cells to eliminate them if needed, making this approach promising for treating patients with specific types of medulloblastoma.
This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC). To manufacture BPX101, APCs collected in a single leukapheresis were transduced with adenoviral vector Ad5f35 encoding inducible human (ih)-CD40, followed by incubation with protein PA001, which contains the extracellular domain of human prostate-specific membrane antigen. The ih-CD40 represents a modified chimeric version of the dendritic cell (DC) co-stimulatory molecule, CD40, which responds to a bioinert membrane-permeable activating dimerizer drug, rimiducid (AP1903), permitting temporally controlled, lymphoid-localized, DC-specific activation.
View Article and Find Full Text PDFArticle Synopsis
- Mesenchymal stem cells (MSCs) have low immunogenicity and immunomodulatory abilities, suggesting safe transplantation in immunocompetent recipients without immunosuppression.
- In an experiment with baboons, three groups received either no treatment, MSCs from the same donor, or MSCs from different donors, with muscle biopsies showing MSC persistence in 50% of animals after treatment.
- The study found that while recipient baboons developed alloantibodies against donor cells, their overall T-cell response remained unaffected, indicating that repeated high doses of allogeneic MSCs can modulate immune responses, potentially enhancing MSC survival.
Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support hematopoietic progenitors in vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment and lessen graft-versus-host disease (GVHD); however, the safety and feasibility of this approach needed to be established. In an open-label, multicenter trial, we coadministered culture-expanded MSCs with HLA-identical sibling-matched HSCs in hematologic malignancy patients.
View Article and Find Full Text PDFObjective: Mesenchymal stem cells (MSCs), multipotential cells that reside within the bone marrow, can be induced to differentiate into various components of the marrow microenvironment, such as bone, adipose, and stromal tissues. The bone marrow microenvironment is vital to the development, differentiation, and regulation of the lymphohematopoietic system. We hypothesized that the activities of MSCs in the bone marrow microenvironment might also include immunomodulatory effects on lymphocytes.
View Article and Find Full Text PDF